Skip to medicine information
Protein Simülasyonları ve 3D Modelleme Medicine information · English

Voclosporin

Use and treatment setting

Voclosporin, marketed as Lupkynis, is an oral calcineurin-inhibitor immunosuppressant for adults with active lupus nephritis. It is used with a background immunosuppressive regimen under specialist supervision. That intended combination should not be confused with a blanket rule that every accompanying immunosuppressant is forbidden. The U.S. label does not establish safety and efficacy with cyclophosphamide and does not recommend that combination.

Kidney function, blood pressure and potassium

Kidney function, blood pressure and potassium are central to monitoring. Voclosporin can reduce kidney filtration and cause hypertension or hyperkalaemia. ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics can increase the potassium concern; they are not automatically contraindicated, but monitoring and an individual plan matter. Tell the treatment team about reduced urine output, unusual weakness or a significant change in health. Do not adjust blood-pressure or kidney medicines independently.

Interactions that change drug exposure

Strong systemic CYP3A4 inhibitors can markedly increase voclosporin exposure and are contraindicated; clarithromycin is a named example. Moderate inhibitors such as fluconazole, verapamil and diltiazem also increase exposure and require a clinician-directed adjustment. Strong or moderate CYP3A4 inducers can reduce exposure and should be avoided. A topical ketoconazole shampoo is not interchangeable with systemic ketoconazole for this interaction mechanism.

Effects on other medicines and urgent symptoms

Voclosporin can increase digoxin exposure through P-glycoprotein inhibition and can affect certain statins through OATP transporters. The prescriber may need extra monitoring for digoxin toxicity or statin-associated muscle injury. QT-prolonging medicines require a separate review, particularly when other cardiac risks are present. The label also warns about serious infections and malignancies associated with immunosuppression. Severe infection, a serious allergic reaction, new seizures, marked confusion, visual disturbance, fainting or palpitations require prompt assessment.

Pregnancy, breastfeeding and everyday use

The U.S. label advises avoiding the ethanol-containing formulation in pregnancy; background medicines such as mycophenolate have their own important reproductive risks. Current lactation labeling reports small quantities of voclosporin in human milk, rather than providing a universal instruction never to breastfeed. The clinician should weigh breastfeeding benefits, maternal treatment need and possible infant effects. Common reported effects include reduced kidney filtration, hypertension, diarrhoea, headache and tremor. Avoid grapefruit and review live vaccines with the team. This summary supplies no dose-change or substitution recipe.

Sources and scope

This English summary describes the referenced U.S. product information; local authorisations, age limits and formulations may differ. It is not a dosing guide or an independent clinical review. A missing interaction entry does not establish safety.